ID   CO3_RAT                 Reviewed;        1663 AA.
AC   P01026; Q9ET19; Q9QV57; Q9QV58;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1990, sequence version 3.
DT   24-JUL-2024, entry version 199.
DE   RecName: Full=Complement C3;
DE   Contains:
DE     RecName: Full=Complement C3 beta chain;
DE   Contains:
DE     RecName: Full=C3-beta-c;
DE              Short=C3bc;
DE     AltName: Full=Neutrophil chemotactic factor-2;
DE              Short=ENCF-2;
DE   Contains:
DE     RecName: Full=Complement C3 alpha chain;
DE   Contains:
DE     RecName: Full=C3a anaphylatoxin;
DE     AltName: Full=Neutrophil chemotactic factor-1;
DE              Short=ENCF-1;
DE   Contains:
DE     RecName: Full=Acylation stimulating protein;
DE              Short=ASP;
DE     AltName: Full=C3adesArg;
DE   Contains:
DE     RecName: Full=Complement C3b alpha' chain;
DE   Contains:
DE     RecName: Full=Complement C3c alpha' chain fragment 1;
DE   Contains:
DE     RecName: Full=Complement C3dg fragment;
DE   Contains:
DE     RecName: Full=Complement C3g fragment;
DE   Contains:
DE     RecName: Full=Complement C3d fragment;
DE   Contains:
DE     RecName: Full=Complement C3f fragment;
DE   Contains:
DE     RecName: Full=Complement C3c alpha' chain fragment 2;
DE   Flags: Precursor;
GN   Name=C3;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Wistar; TISSUE=Liver;
RX   PubMed=2336397; DOI=10.1093/nar/18.8.2178;
RA   Misumi Y., Sohda M., Ikehara Y.;
RT   "Nucleotide and deduced amino acid sequence of rat complement C3.";
RL   Nucleic Acids Res. 18:2178-2178(1990).
RN   [2]
RP   PROTEIN SEQUENCE OF 568-592 AND 671-687, IDENTIFICATION OF C3A
RP   ANAPHYLATOXIN AND C3-BETA-C, AND FUNCTION.
RC   TISSUE=Neutrophil;
RX   PubMed=8352775; DOI=10.1006/bbrc.1993.1947;
RA   Nakagawa H., Komorita N.;
RT   "Complement component C3-derived neutrophil chemotactic factors purified
RT   from exudate of rat carrageenin-induced inflammation.";
RL   Biochem. Biophys. Res. Commun. 194:1181-1187(1993).
RN   [3]
RP   PROTEIN SEQUENCE OF 671-748.
RX   PubMed=309768; DOI=10.1021/bi00616a027;
RA   Jacobs J.W., Rubin J.S., Hugli T.E., Bogardt R.A. Jr., Mariz I.K.,
RA   Daniels J.S., Daughaday W.H., Bradshaw R.A.;
RT   "Purification, characterization, and amino acid sequence of rat
RT   anaphylatoxin (C3a).";
RL   Biochemistry 17:5031-5038(1978).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 671-748.
RC   STRAIN=Sprague-Dawley; TISSUE=Liver;
RA   Wahrmann M., Krieger S., Liewehr A.;
RT   "Nucleotide and deduced amino acid sequence of rat complement component C3a
RT   derived from Sprague-Dawley strain.";
RL   Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   PROTEIN SEQUENCE OF 960-969, AND X-RAY CRYSTALLOGRAPHY (1.44 ANGSTROMS) OF
RP   1010-1286.
RX   PubMed=10825534; DOI=10.1016/s0167-4838(00)00040-6;
RA   Zanotti G., Bassetto A., Battistutta R., Folli C., Arcidiaco P.,
RA   Stoppini M., Berni R.;
RT   "Structure at 1.44 A resolution of an N-terminally truncated form of the
RT   rat serum complement C3d fragment.";
RL   Biochim. Biophys. Acta 1478:232-238(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1316-1595.
RX   PubMed=2674144; DOI=10.1016/s0021-9258(19)84798-1;
RA   Sundstrom S.A., Komm B.S., Ponce-De-Leon H., Yi Z., Teuscher C.,
RA   Lyttle C.R.;
RT   "Estrogen regulation of tissue-specific expression of complement C3.";
RL   J. Biol. Chem. 264:16941-16947(1989).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-671, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: C3 plays a central role in the activation of the complement
CC       system. Its processing by C3 convertase is the central reaction in both
CC       classical and alternative complement pathways. After activation C3b can
CC       bind covalently, via its reactive thioester, to cell surface
CC       carbohydrates or immune aggregates. {ECO:0000269|PubMed:8352775}.
CC   -!- FUNCTION: Derived from proteolytic degradation of complement C3, C3a
CC       anaphylatoxin is a mediator of local inflammatory process. It induces
CC       the contraction of smooth muscle, increases vascular permeability and
CC       causes histamine release from mast cells and basophilic leukocytes. In
CC       chronic inflammation, acts as a chemoattractant for neutrophils
CC       (PubMed:8352775). {ECO:0000269|PubMed:8352775}.
CC   -!- FUNCTION: [C3-beta-c]: Acts as a chemoattractant for neutrophils in
CC       chronic inflammation. {ECO:0000269|PubMed:8352775}.
CC   -!- FUNCTION: [Acylation stimulating protein]: Adipogenic hormone that
CC       stimulates triglyceride (TG) synthesis and glucose transport in
CC       adipocytes, regulating fat storage and playing a role in postprandial
CC       TG clearance. Appears to stimulate TG synthesis via activation of the
CC       PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the
CC       phosphorylation, ARRB2-mediated internalization and recycling of C5AR2
CC       (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: C3 precursor is first processed by the removal of 4 Arg
CC       residues, forming two chains, beta and alpha, linked by a disulfide
CC       bond. C3 convertase activates C3 by cleaving the alpha chain, releasing
CC       C3a anaphylatoxin and generating C3b (beta chain + alpha' chain). Forms
CC       the pro-C3-convertase enzyme complex by binding to Complement factor B
CC       Bb fragment (Bb), which is then stabilized by binding CFP, allowing the
CC       complex to become active (By similarity). The interaction with Bb is
CC       dependent on Mg2+ (By similarity). C3b interacts with CR1 (via Sushi 8
CC       and Sushi 9 domains). C3b interacts with CFH. C3d interacts with CFH.
CC       C3dg interacts with CR2 (via the N-terminal Sushi domains 1 and 2).
CC       During pregnancy, C3dg exists as a complex (probably a 2:2:2
CC       heterohexamer) with AGT and the proform of PRG2. Interacts with VSIG4.
CC       Interacts with S.aureus immunoglobulin-binding protein sbi, this
CC       prevents interaction between C3dg and CR2. Interacts with S.aureus fib.
CC       Interacts (both C3a and ASP) with C5AR2; the interaction occurs with
CC       higher affinity for ASP, enhancing the phosphorylation and activation
CC       of C5AR2, recruitment of ARRB2 to the cell surface and endocytosis of
CC       GRP77. {ECO:0000250|UniProtKB:P01024}.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- PTM: C3b is rapidly split in two positions by factor I and a cofactor
CC       to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is
CC       slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha'
CC       chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other
CC       proteases produce other fragments such as C3d or C3g. C3a is further
CC       processed by carboxypeptidases to release the C-terminal arginine
CC       residue generating the acylation stimulating protein (ASP). Levels of
CC       ASP are increased in adipocytes in the postprandial period and by
CC       dietary chylomicrons (By similarity). {ECO:0000250}.
CC   -!- PTM: Phosphorylated by FAM20C in the extracellular medium.
CC       {ECO:0000250|UniProtKB:P01024}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X52477; CAA36716.1; -; mRNA.
DR   EMBL; AF286158; AAG00532.1; -; mRNA.
DR   EMBL; M29866; AAA40837.1; -; mRNA.
DR   PIR; S15764; C3RT.
DR   RefSeq; NP_058690.2; NM_016994.2.
DR   PDB; 1QQF; X-ray; 1.45 A; A=1010-1286.
DR   PDB; 1QSJ; X-ray; 1.90 A; A/B/C/D=1010-1286.
DR   PDBsum; 1QQF; -.
DR   PDBsum; 1QSJ; -.
DR   AlphaFoldDB; P01026; -.
DR   SMR; P01026; -.
DR   BioGRID; 246419; 3.
DR   IntAct; P01026; 1.
DR   MINT; P01026; -.
DR   STRING; 10116.ENSRNOP00000066885; -.
DR   MEROPS; I39.950; -.
DR   CarbonylDB; P01026; -.
DR   GlyCosmos; P01026; 2 sites, No reported glycans.
DR   GlyGen; P01026; 2 sites.
DR   iPTMnet; P01026; -.
DR   PhosphoSitePlus; P01026; -.
DR   jPOST; P01026; -.
DR   PaxDb; 10116-ENSRNOP00000066885; -.
DR   GeneID; 24232; -.
DR   KEGG; rno:24232; -.
DR   AGR; RGD:2232; -.
DR   CTD; 718; -.
DR   RGD; 2232; C3.
DR   eggNOG; KOG1366; Eukaryota.
DR   InParanoid; P01026; -.
DR   OrthoDB; 4033541at2759; -.
DR   PhylomeDB; P01026; -.
DR   Reactome; R-RNO-173736; Alternative complement activation.
DR   Reactome; R-RNO-174577; Activation of C3 and C5.
DR   Reactome; R-RNO-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   Reactome; R-RNO-375276; Peptide ligand-binding receptors.
DR   Reactome; R-RNO-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-RNO-418594; G alpha (i) signalling events.
DR   Reactome; R-RNO-6798695; Neutrophil degranulation.
DR   Reactome; R-RNO-8957275; Post-translational protein phosphorylation.
DR   Reactome; R-RNO-977606; Regulation of Complement cascade.
DR   EvolutionaryTrace; P01026; -.
DR   PRO; PR:P01026; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0009986; C:cell surface; ISO:RGD.
DR   GO; GO:0005576; C:extracellular region; ISO:RGD.
DR   GO; GO:0005615; C:extracellular space; IDA:RGD.
DR   GO; GO:0032991; C:protein-containing complex; ISO:RGD.
DR   GO; GO:0031715; F:C5L2 anaphylatoxin chemotactic receptor binding; ISS:UniProtKB.
DR   GO; GO:0004866; F:endopeptidase inhibitor activity; IEA:InterPro.
DR   GO; GO:0008289; F:lipid binding; IDA:RGD.
DR   GO; GO:0097242; P:amyloid-beta clearance; ISO:RGD.
DR   GO; GO:0006935; P:chemotaxis; IEA:UniProtKB-KW.
DR   GO; GO:0006956; P:complement activation; IDA:RGD.
DR   GO; GO:0006957; P:complement activation, alternative pathway; IEA:UniProtKB-KW.
DR   GO; GO:0006958; P:complement activation, classical pathway; TAS:RGD.
DR   GO; GO:0002430; P:complement receptor mediated signaling pathway; ISO:RGD.
DR   GO; GO:0097278; P:complement-dependent cytotoxicity; ISO:RGD.
DR   GO; GO:0150062; P:complement-mediated synapse pruning; ISO:RGD.
DR   GO; GO:0006631; P:fatty acid metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0016322; P:neuron remodeling; ISO:RGD.
DR   GO; GO:0035846; P:oviduct epithelium development; ISO:RGD.
DR   GO; GO:0001970; P:positive regulation of activation of membrane attack complex; ISO:RGD.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISO:RGD.
DR   GO; GO:2000427; P:positive regulation of apoptotic cell clearance; ISO:RGD.
DR   GO; GO:0048639; P:positive regulation of developmental growth; IDA:RGD.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:RGD.
DR   GO; GO:0045745; P:positive regulation of G protein-coupled receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0010828; P:positive regulation of glucose transmembrane transport; ISS:UniProtKB.
DR   GO; GO:0010884; P:positive regulation of lipid storage; ISS:UniProtKB.
DR   GO; GO:0050766; P:positive regulation of phagocytosis; ISO:RGD.
DR   GO; GO:0060100; P:positive regulation of phagocytosis, engulfment; ISO:RGD.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0048260; P:positive regulation of receptor-mediated endocytosis; ISO:RGD.
DR   GO; GO:0001798; P:positive regulation of type IIa hypersensitivity; ISO:RGD.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; ISO:RGD.
DR   GO; GO:0010866; P:regulation of triglyceride biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0009617; P:response to bacterium; ISO:RGD.
DR   GO; GO:0032355; P:response to estradiol; IEP:RGD.
DR   GO; GO:0043627; P:response to estrogen; IEP:RGD.
DR   GO; GO:0051384; P:response to glucocorticoid; IEP:RGD.
DR   GO; GO:0032026; P:response to magnesium ion; IEP:RGD.
DR   GO; GO:0032570; P:response to progesterone; IEP:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEP:RGD.
DR   GO; GO:0060041; P:retina development in camera-type eye; ISO:RGD.
DR   GO; GO:0002507; P:tolerance induction; IEP:RGD.
DR   GO; GO:0035886; P:vascular associated smooth muscle cell differentiation; ISO:RGD.
DR   GO; GO:0150064; P:vertebrate eye-specific patterning; ISO:RGD.
DR   CDD; cd00017; ANATO; 1.
DR   CDD; cd02896; complement_C3_C4_C5; 1.
DR   CDD; cd03583; NTR_complement_C3; 1.
DR   Gene3D; 1.50.10.20; -; 1.
DR   Gene3D; 2.20.130.20; -; 1.
DR   Gene3D; 2.40.50.120; -; 1.
DR   Gene3D; 2.60.120.1540; -; 1.
DR   Gene3D; 2.60.40.1930; -; 3.
DR   Gene3D; 2.60.40.1940; -; 1.
DR   Gene3D; 6.20.50.160; -; 1.
DR   Gene3D; 2.60.40.690; Alpha-macroglobulin, receptor-binding domain; 1.
DR   Gene3D; 1.20.91.20; Anaphylotoxins (complement system); 1.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 2.
DR   InterPro; IPR009048; A-macroglobulin_rcpt-bd.
DR   InterPro; IPR036595; A-macroglobulin_rcpt-bd_sf.
DR   InterPro; IPR050473; A2M/Complement_sys.
DR   InterPro; IPR011625; A2M_N_BRD.
DR   InterPro; IPR047565; Alpha-macroglob_thiol-ester_cl.
DR   InterPro; IPR011626; Alpha-macroglobulin_TED.
DR   InterPro; IPR000020; Anaphylatoxin/fibulin.
DR   InterPro; IPR018081; Anaphylatoxin_comp_syst.
DR   InterPro; IPR001840; Anaphylatoxn_comp_syst_dom.
DR   InterPro; IPR041425; C3/4/5_MG1.
DR   InterPro; IPR049466; C3_CUB1.
DR   InterPro; IPR048848; C3_CUB2.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR001599; Macroglobln_a2.
DR   InterPro; IPR019742; MacrogloblnA2_CS.
DR   InterPro; IPR002890; MG2.
DR   InterPro; IPR041555; MG3.
DR   InterPro; IPR040839; MG4.
DR   InterPro; IPR001134; Netrin_domain.
DR   InterPro; IPR018933; Netrin_module_non-TIMP.
DR   InterPro; IPR035815; NTR_complement_C3.
DR   InterPro; IPR008930; Terpenoid_cyclase/PrenylTrfase.
DR   InterPro; IPR008993; TIMP-like_OB-fold.
DR   PANTHER; PTHR11412:SF81; COMPLEMENT C3; 1.
DR   PANTHER; PTHR11412; MACROGLOBULIN / COMPLEMENT; 1.
DR   Pfam; PF00207; A2M; 1.
DR   Pfam; PF07703; A2M_BRD; 1.
DR   Pfam; PF07677; A2M_recep; 1.
DR   Pfam; PF01821; ANATO; 1.
DR   Pfam; PF21406; C3_CUB1; 1.
DR   Pfam; PF21308; C3_CUB2; 1.
DR   Pfam; PF17790; MG1; 1.
DR   Pfam; PF01835; MG2; 1.
DR   Pfam; PF17791; MG3; 1.
DR   Pfam; PF17789; MG4; 1.
DR   Pfam; PF01759; NTR; 1.
DR   Pfam; PF07678; TED_complement; 1.
DR   PRINTS; PR00004; ANAPHYLATOXN.
DR   SFLD; SFLDG01179; Complement_C3/C4_Like; 1.
DR   SMART; SM01360; A2M; 1.
DR   SMART; SM01359; A2M_N_2; 1.
DR   SMART; SM01361; A2M_recep; 1.
DR   SMART; SM00104; ANATO; 1.
DR   SMART; SM00643; C345C; 1.
DR   SMART; SM01419; Thiol-ester_cl; 1.
DR   SUPFAM; SSF49410; Alpha-macroglobulin receptor domain; 1.
DR   SUPFAM; SSF47686; Anaphylotoxins (complement system); 1.
DR   SUPFAM; SSF48239; Terpenoid cyclases/Protein prenyltransferases; 1.
DR   SUPFAM; SSF50242; TIMP-like; 1.
DR   PROSITE; PS00477; ALPHA_2_MACROGLOBULIN; 1.
DR   PROSITE; PS01177; ANAPHYLATOXIN_1; 1.
DR   PROSITE; PS01178; ANAPHYLATOXIN_2; 1.
DR   PROSITE; PS50189; NTR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Chemotaxis; Cleavage on pair of basic residues;
KW   Complement alternate pathway; Complement pathway;
KW   Direct protein sequencing; Disulfide bond; Fatty acid metabolism;
KW   Glycoprotein; Immunity; Inflammatory response; Innate immunity;
KW   Lipid metabolism; Phosphoprotein; Reference proteome; Secreted; Signal;
KW   Thioester bond.
FT   SIGNAL          1..24
FT   CHAIN           25..1663
FT                   /note="Complement C3"
FT                   /id="PRO_0000005937"
FT   CHAIN           25..666
FT                   /note="Complement C3 beta chain"
FT                   /id="PRO_0000005938"
FT   CHAIN           568..666
FT                   /note="C3-beta-c"
FT                   /id="PRO_0000395292"
FT   CHAIN           671..1663
FT                   /note="Complement C3 alpha chain"
FT                   /id="PRO_0000005939"
FT   CHAIN           671..748
FT                   /note="C3a anaphylatoxin"
FT                   /id="PRO_0000005940"
FT   CHAIN           671..747
FT                   /note="Acylation stimulating protein"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000419937"
FT   CHAIN           749..1663
FT                   /note="Complement C3b alpha' chain"
FT                   /id="PRO_0000005941"
FT   CHAIN           749..959
FT                   /note="Complement C3c alpha' chain fragment 1"
FT                   /id="PRO_0000273950"
FT   CHAIN           960..1303
FT                   /note="Complement C3dg fragment"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000273951"
FT   CHAIN           960..1001
FT                   /note="Complement C3g fragment"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000273952"
FT   CHAIN           1002..1303
FT                   /note="Complement C3d fragment"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000273953"
FT   PEPTIDE         1304..1320
FT                   /note="Complement C3f fragment"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000273954"
FT   CHAIN           1321..1663
FT                   /note="Complement C3c alpha' chain fragment 2"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000273955"
FT   DOMAIN          693..728
FT                   /note="Anaphylatoxin-like"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00022"
FT   DOMAIN          1518..1661
FT                   /note="NTR"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00295"
FT   REGION          1634..1659
FT                   /note="Interaction with CFP/properdin"
FT                   /evidence="ECO:0000250|UniProtKB:P01024"
FT   SITE            747..748
FT                   /note="Cleavage; by carboxypeptidases"
FT                   /evidence="ECO:0000250"
FT   SITE            748..749
FT                   /note="Cleavage; by C3 convertase"
FT   SITE            959..960
FT                   /note="Cleavage; by factor I"
FT                   /evidence="ECO:0000255"
FT   SITE            1303..1304
FT                   /note="Cleavage; by factor I"
FT                   /evidence="ECO:0000250"
FT   SITE            1320..1321
FT                   /note="Cleavage; by factor I"
FT                   /evidence="ECO:0000250"
FT   SITE            1663
FT                   /note="Coordinates Mg2+ for interaction with Complement
FT                   factor B Bb fragment"
FT                   /evidence="ECO:0000250|UniProtKB:P01024"
FT   MOD_RES         40
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P01024"
FT   MOD_RES         297
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P01024"
FT   MOD_RES         303
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P01024"
FT   MOD_RES         671
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         968
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P01024"
FT   MOD_RES         1321
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P01024"
FT   MOD_RES         1573
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P01024"
FT   CARBOHYD        939
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000305"
FT   CARBOHYD        1617
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000305"
FT   DISULFID        558..816
FT                   /note="Interchain (between beta and alpha chains)"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00022,
FT                   ECO:0000255|PROSITE-ProRule:PRU00295"
FT   DISULFID        626..661
FT                   /evidence="ECO:0000250"
FT   DISULFID        693..720
FT                   /evidence="ECO:0000250"
FT   DISULFID        694..727
FT                   /evidence="ECO:0000250"
FT   DISULFID        707..728
FT                   /evidence="ECO:0000250"
FT   DISULFID        873..1513
FT                   /evidence="ECO:0000250"
FT   DISULFID        1101..1158
FT                   /evidence="ECO:0000250"
FT   DISULFID        1358..1489
FT                   /evidence="ECO:0000250"
FT   DISULFID        1389..1458
FT                   /evidence="ECO:0000250"
FT   DISULFID        1506..1511
FT                   /evidence="ECO:0000250"
FT   DISULFID        1518..1590
FT                   /evidence="ECO:0000250"
FT   DISULFID        1537..1661
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        1010..1013
FT                   /note="Isoglutamyl cysteine thioester (Cys-Gln)"
FT                   /evidence="ECO:0000250"
FT   CONFLICT        704
FT                   /note="P -> K (in Ref. 4; AAG00532)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        721..722
FT                   /note="LK -> KL (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   HELIX           1013..1031
FT                   /evidence="ECO:0007829|PDB:1QQF"
FT   HELIX           1034..1037
FT                   /evidence="ECO:0007829|PDB:1QQF"
FT   HELIX           1039..1041
FT                   /evidence="ECO:0007829|PDB:1QQF"
FT   HELIX           1042..1057
FT                   /evidence="ECO:0007829|PDB:1QQF"
FT   HELIX           1076..1089
FT                   /evidence="ECO:0007829|PDB:1QQF"
FT   TURN            1090..1092
FT                   /evidence="ECO:0007829|PDB:1QQF"
FT   HELIX           1097..1111
FT                   /evidence="ECO:0007829|PDB:1QQF"
FT   HELIX           1127..1134
FT                   /evidence="ECO:0007829|PDB:1QQF"
FT   HELIX           1139..1158
FT                   /evidence="ECO:0007829|PDB:1QQF"
FT   TURN            1159..1161
FT                   /evidence="ECO:0007829|PDB:1QQF"
FT   HELIX           1165..1180
FT                   /evidence="ECO:0007829|PDB:1QQF"
FT   HELIX           1186..1198
FT                   /evidence="ECO:0007829|PDB:1QQF"
FT   HELIX           1206..1213
FT                   /evidence="ECO:0007829|PDB:1QQF"
FT   TURN            1216..1218
FT                   /evidence="ECO:0007829|PDB:1QQF"
FT   HELIX           1226..1242
FT                   /evidence="ECO:0007829|PDB:1QQF"
FT   TURN            1246..1248
FT                   /evidence="ECO:0007829|PDB:1QSJ"
FT   HELIX           1249..1258
FT                   /evidence="ECO:0007829|PDB:1QQF"
FT   HELIX           1269..1285
FT                   /evidence="ECO:0007829|PDB:1QQF"
SQ   SEQUENCE   1663 AA;  186460 MW;  2F87CCB143CDD4BC CRC64;
     MGPTSGSQLL VLLLLLASSL LALGSPMYSI ITPNVLRLES EETFILEAHD AQGDVPVTVT
     VQDFLKKQVL TSEKTVLTGA TGHLNRVFIK IPASKEFNAD KGHKYVTVVA NFGATVVEKA
     VLVSFQSGYL FIQTDKTIYT PGSTVFYRIF TVDNNLLPVG KTVVIVIETP DGVPIKRDIL
     SSHNQYGILP LSWNIPELVN MGQWKIRAFY EHAPKQTFSA EFEVKEYVLP SFEVLVEPTE
     KFYYIHGPKG LEVSITARFL YGKNVDGTAF VIFGVQDEDK KISLALSLTR VLIEDGSGEA
     VLSRKVLMDG VRPSSPEALV GKSLYVSVTV ILHSGSDMVE AERSGIPIVT SPYQIHFTKT
     PKFFKPAMPF DLMVFVTNPD GSPARRVPVV TQGSDAQALT QDDGVAKLSV NTPNNRQPLT
     ITVSTKKEGI PDARQATRTM QAQPYSTMHN SNNYLHLSVS RVELKPGDNL NVNFHLRTDA
     GQEAKIRYYT YLVMNKGKLL KAGRQVREPG QDLVVLSLPI TPEFIPSFRL VAYYTLIGAN
     GQREVVADSV WVDVKDSCVG TLVVKGDPRD NRQPAPGHQT TLRIEGNQGA RVGLVAVDKG
     VFVLNKKNKL TQSKIWDVVE KADIGCTPGS GKNYAGVFMD AGLTFKTNQG LQTDQREDPE
     CAKPAARRRR SVQLMERRMD KAGQYTDKGL RKCCEDGMRD IPMPYSCQRR ARLITQGESC
     LKAFMDCCNY ITKLREQHRR DHVLGLARSD VDEDIIPEED IISRSHFPES WLWTIEELKE
     PEKNGISTKV MNIFLKDSIT TWEILAVSLS DKKGICVADP YEITVMQDFF IDLRLPYSVV
     RNEQVEIRAV LFNYREQEKL KVRVELLHNP AFCSMATAKK RYYQTIEIPP KSSVAVPYVI
     VPLKIGLQEV EVKAAVFNHF ISDGVKKILK VVPEGMRVNK TVAVRTLDPE HLNQGGVQRE
     DVNAADLSDQ VPDTDSETRI LLQGTPVAQM AEDAVDGERL KHLIVTPSGC GEQNMIGMTP
     TVIAVHYLDQ TEQWEKFGLE KRQEALELIK KGYTQQLAFK QPISAYAAFN NRPPSTWLTA
     MWSRSFSLAA NLIAIDSQVL CGAVKWLILE KQKPDGVFQE DGPVIHQEMI GGFRNTKEAD
     VSLTAFVLIA LQEARDICEG QVNSLPGSIN KAGEYLEASY LNLQRPYTVA IAGYALALMN
     KLEEPYLTKF LNTAKDRNRW EEPGQQLYNV EATSYALLAL LLLKDFDSVP PVVRWLNDER
     YYGGGYGSTQ ATFMVFQALA QYRADVPDHK DLNMDVSLHL PSRSSPTVFR LLWESGSLLR
     SEETKQNEGF SLTAKGKGQG TLSVVTVYHA KVKGKTTCKK FDLRVTIKPA PETAKKPQDA
     KSSMILDICT RYLGDVDATM SILDISMMTG FIPDTNDLEL LSSGVDRYIS KYEMDKAFSN
     KNTLIIYLEK ISHSEEDCLS FKVHQFFNVG LIQPGSVKVY SYYNLEESCT RFYHPEKDDG
     MLSKLCHNEM CRCAEENCFM HQSQDQVSLN ERLDKACEPG VDYVYKTKLT TIELSDDFDE
     YIMTIEQVIK SGSDEVQAGQ ERRFISHVKC RNALKLQKGK QYLMWGLSSD LWGEKPNTSY
     IIGKDTWVEH WPEAEERQDQ KNQKQCEDLG AFTETMVVFG CPN
//
